Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

RELB Antikörper (C-Term)

RELB Reaktivität: Human, Maus WB, IP, IHC (p), ChIP Wirt: Kaninchen Polyclonal unconjugated
Produktnummer ABIN2855360
  • Target Alle RELB Antikörper anzeigen
    RELB (V-Rel Reticuloendotheliosis Viral Oncogene Homolog B (RELB))
    Bindungsspezifität
    • 16
    • 15
    • 12
    • 7
    • 5
    • 5
    • 5
    • 5
    • 3
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    C-Term
    Reaktivität
    • 100
    • 71
    • 35
    • 12
    • 12
    • 8
    • 6
    • 6
    • 5
    • 3
    • 1
    • 1
    • 1
    Human, Maus
    Wirt
    • 99
    • 5
    Kaninchen
    Klonalität
    • 94
    • 10
    Polyklonal
    Konjugat
    • 57
    • 5
    • 4
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    Dieser RELB Antikörper ist unkonjugiert
    Applikation
    • 84
    • 27
    • 27
    • 24
    • 17
    • 14
    • 9
    • 8
    • 7
    • 5
    • 4
    • 2
    • 2
    • 1
    Western Blotting (WB), Immunoprecipitation (IP), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Chromatin Immunoprecipitation (ChIP)
    Produktmerkmale
    Rabbit Polyclonal antibody to RelB (v-rel reticuloendotheliosis viral oncogene homolog B)
    RelB antibody
    Aufreinigung
    Purified by antigen-affinity chromatography.
    Immunogen
    Recombinant protein encompassing a sequence within the C-terminus region of human RelB. The exact sequence is proprietary.
    Isotyp
    IgG
    Top Product
    Discover our top product RELB Primärantikörper
  • Applikationshinweise
    Suggested dilution Reference ChIP assay Assay-dependent dilution IHC (Formalin-fixed paraffin-embedded sections) 1:100-1:1000* Immunoprecipitation 1:100-1:500* Western blot 1:1000-1:10000* Not tested in other applications. *Optimal dilutions/concentrations should be determined by the researcher.Suggested dilutionReferenceChIP assayAssay-dependent dilution IHC (Formalin-fixed paraffin-embedded sections)1:100-1:1000* Immunoprecipitation1:100-1:500* Western blot1:1000-1:10000*
    Kommentare

    Positive Control: Jurkat , NIH-3T3

    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Konzentration
    0.81 mg/mL
    Buffer
    1XPBS, 1 % BSA, 20 % Glycerol ( pH 7). 0.01 % Thimerosal was added as a preservative.
    Konservierungsmittel
    Thimerosal (Merthiolate)
    Vorsichtsmaßnahmen
    This product contains Thimerosal (Merthiolate): a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    -20 °C
    Informationen zur Lagerung
    Keep as concentrated solution. Aliquot and store at -20°C or below. Avoid multiple freeze-thaw cycles.
  • Target
    RELB (V-Rel Reticuloendotheliosis Viral Oncogene Homolog B (RELB))
    Andere Bezeichnung
    RelB (RELB Produkte)
    Synonyme
    shep antikoerper, I-REL antikoerper, IREL antikoerper, REL-B antikoerper, XRelB antikoerper, relb-A antikoerper, GC-rich antikoerper, avian reticuloendotheliosis viral (v-rel) oncogene related B antikoerper, RELB proto-oncogene, NF-kB subunit antikoerper, v-rel avian reticuloendotheliosis viral oncogene homolog B S homeolog antikoerper, Relb antikoerper, RELB antikoerper, relb.S antikoerper
    Hintergrund
    NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49.

    Cellular Localization: Nucleus
    Molekulargewicht
    62 kDa
    Gen-ID
    5971
    Pathways
    NF-kappaB Signalweg, RTK Signalweg
Sie sind hier:
Kundenservice